Table 6 |
|||||||
|
Mutation analysis |
|||||||
|
total |
% |
SMPC(+) cases |
% |
SMPC(-) cases |
% |
P value |
|
|
|
|||||||
|
No. |
33 |
19 |
14 |
||||
|
EGFR mutation |
|||||||
|
Negative |
13 |
39 |
5 |
26 |
8 |
57 |
0.076* |
|
Positive |
20 |
61 |
14 |
74 |
6 |
43 |
|
|
ex19 |
7 |
35§ |
5 |
36§ |
2 |
33§ |
0.664* |
|
ex21 |
13 |
65§ |
9 |
64§ |
4 |
67§ |
|
|
KRAS mutation |
|||||||
|
Negative |
33 |
100 |
19 |
100 |
14 |
100 |
- |
|
Positive |
0 |
0 |
0 |
0 |
|||
|
|
|||||||
|
No., number of patients; EGFR, epidermal growth factor receptor; SMPC, stromal micropapillary component * Fisher's exact probability test § Rate of positive cases at ex19 and 21 in EGFR mutation positive cases, respectively. |
|||||||
|
Ohe et al. Diagnostic Pathology 2012 7:3 doi:10.1186/1746-1596-7-3 |
|||||||
